Silverback Therapeutics said late Thursday its initial public offering of stock raised gross proceeds of $241 million after the Seattle-based biotech upsized its planned share sale. Evidently responding to strong investor interest in its technology for targeting solid tumors, the company increased the IPO that as recently as Nov. 30 was expected to raise about […]
source https://www.seattletimes.com/business/seattle-biotech-silverback-therapeutics-prices-upsized-ipo/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_technology
No comments:
Post a Comment